Fady Ibraham Malik Sells 2,200 Shares of Cytokinetics (NASDAQ:CYTK) Stock
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 2,200 shares of the company's stock in a transaction that occurred on Tuesday, December 16th. The shares were...
MarketBeat·1d ago
More News
Sanders Morris Harris LLC Takes $1.18 Million Position in Cytokinetics, Incorporated $CYTK
Sanders Morris Harris LLC acquired a new position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC...
MarketBeat·2d ago
Mirador Capital Partners LP Acquires 53,020 Shares of Cytokinetics, Incorporated $CYTK
Mirador Capital Partners LP increased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 36.7% during the third quarter, according to its most recent Form 13F filing...
MarketBeat·2d ago
Cytokinetics (NASDAQ:CYTK) EVP Sells $134,728.00 in Stock
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 2,200 shares of Cytokinetics stock in a transaction that occurred on Tuesday, December 16th. The stock was sold...
MarketBeat·2d ago
Frazier Life Sciences Management L.P. Invests $18.33 Million in Cytokinetics, Incorporated $CYTK
Frazier Life Sciences Management L.P. acquired a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the second quarter, according to its most recent disclosure with the Securities...
MarketBeat·5d ago
Needham & Company LLC Reaffirms "Buy" Rating for Cytokinetics (NASDAQ:CYTK)
Needham & Company LLC reiterated a "buy" rating and issued a $72.00 price objective on shares of Cytokinetics in a research report on Friday...
MarketBeat·5d ago
HighVista Strategies LLC Has $2.27 Million Stock Holdings in Cytokinetics, Incorporated $CYTK
HighVista Strategies LLC lifted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 53.4% during the 2nd quarter, according to the company in its most recent filing...
MarketBeat·7d ago
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 1,042 Shares
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 1,042 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $65.96...
MarketBeat·10d ago
Andrew Callos Sells 1,042 Shares of Cytokinetics (NASDAQ:CYTK) Stock
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 1,042 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of...
MarketBeat·10d ago
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
Key PointsAdded 458,295 shares of Cytokinetics, a $25,187,893 net position change...